Phoenix Financial Ltd. cut its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 43.8% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 794,659 shares of the company's stock after selling 618,765 shares during the quarter. Phoenix Financial Ltd. owned approximately 0.33% of Cellebrite DI worth $15,440,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in CLBT. Bosun Asset Management LLC increased its position in Cellebrite DI by 1.4% in the fourth quarter. Bosun Asset Management LLC now owns 43,307 shares of the company's stock worth $954,000 after purchasing an additional 584 shares during the period. OneDigital Investment Advisors LLC boosted its holdings in Cellebrite DI by 2.5% during the first quarter. OneDigital Investment Advisors LLC now owns 28,591 shares of the company's stock worth $556,000 after buying an additional 688 shares during the last quarter. TD Waterhouse Canada Inc. boosted its holdings in Cellebrite DI by 1.8% during the fourth quarter. TD Waterhouse Canada Inc. now owns 47,497 shares of the company's stock worth $1,046,000 after buying an additional 859 shares during the last quarter. Assetmark Inc. bought a new position in Cellebrite DI during the first quarter worth about $33,000. Finally, Catalyst Capital Advisors LLC bought a new position in Cellebrite DI during the first quarter worth about $51,000. 45.88% of the stock is currently owned by institutional investors and hedge funds.
Cellebrite DI Stock Performance
NASDAQ CLBT traded up $0.10 during trading on Tuesday, hitting $14.47. The stock had a trading volume of 415,606 shares, compared to its average volume of 1,573,302. The company has a market capitalization of $3.46 billion, a PE ratio of -15.06, a P/E/G ratio of 2.89 and a beta of 1.28. The company's 50-day moving average price is $15.74 and its two-hundred day moving average price is $18.63. Cellebrite DI Ltd. has a 12 month low of $11.90 and a 12 month high of $26.30.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.09 by $0.01. Cellebrite DI had a positive return on equity of 35.36% and a negative net margin of 46.34%. The firm had revenue of $107.55 million for the quarter, compared to analysts' expectations of $109.36 million. During the same quarter in the previous year, the business posted $0.08 EPS. The business's quarterly revenue was up 20.0% compared to the same quarter last year. As a group, equities analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.
Analyst Ratings Changes
CLBT has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. reduced their target price on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a report on Monday, May 12th. Needham & Company LLC reiterated a "buy" rating and set a $24.00 price objective on shares of Cellebrite DI in a report on Friday, June 6th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $22.43.
View Our Latest Stock Report on Cellebrite DI
Cellebrite DI Company Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Articles
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
